NCT07367659

Brief Summary

In emergency departments, various methods can be used to reduce the pain experienced by children. However, the most important requirement is that the selected method provides rapid and effective results. Accordingly, it is essential that interventions performed in emergency settings are carried out in a way that enables children to experience the least possible pain and anxiety and that the long-term effects of pain are prevented. Recently, the Helfer Skin Tap Technique (HSTT), which is applied to reduce stress and pain, and the palm stimulator, which is held in the palm and has raised projections on its surface to reduce pain perception by facilitating distraction, have attracted attention. ShotBlocker is a noninvasive, U-shaped plastic device with small projections that is used to reduce injection-related pain in children who are sensitive to pain. In addition, a bee-shaped device called Buzzy®, which combines external cold application and vibration, is also widely used. These methods have been proven to be effective in reducing pain in pediatric patients during invasive procedures such as intramuscular injections and intravenous cannulation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P75+ for not_applicable pain

Timeline
Completed

Started Dec 2025

Shorter than P25 for not_applicable pain

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 25, 2025

Completed
21 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 15, 2026

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

January 17, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 17, 2026

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 26, 2026

Completed
Last Updated

January 26, 2026

Status Verified

January 1, 2026

Enrollment Period

21 days

First QC Date

January 17, 2026

Last Update Submit

January 17, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Pain Rating Scale

    The Wong-Baker FACES Pain Rating Scale was used to assess self-reported pain levels. This scale consists of six facial expressions ranging from "no hurt" (0) to "hurts worst" (10), allowing children to select the face that best represents their level of pain.

    6 weeks

Study Arms (4)

intervention group Palm

EXPERIMENTAL

Palm stimulator

Other: Palm

intervention group ShotBloker

EXPERIMENTAL

ShotBloker device

Other: ShotBlocker

intervention group HSTT

EXPERIMENTAL

HSTT application

Other: HSTT

Control group

NO INTERVENTION

Rutin

Interventions

ShotBlocker is a flat, horseshoe-shaped device used to reduce pain during subcutaneous or intramuscular (IM) injections. It features short, blunt, non-sharp projections approximately 2 mm in height and is designed to be placed against the skin, with a central opening that exposes the injection site. The device is applied to the skin just prior to injection, with its textured surface making contact with the skin. Although the projections do not penetrate the skin, they are believed to create a sensory stimulus associated with pain modulation based on the gate control theory.

intervention group ShotBloker
HSTTOTHER

Helfer Skin Tap Technique: After determining the injection site, gently tap the skin several times with the fingertips of the dominant (most commonly used) hand for approximately 5 seconds to relax the muscle. After the skin is wiped with antiseptic solution and stretched, the cap of the syringe in the dominant (most commonly used) hand is opened. A large V is made with the thumb and index finger of the non-dominant hand. The skin is tapped three times quickly using the whole hand to stimulate the major muscle fibers. The nurse/midwife counts to 3, and the needle is inserted into the muscle at a 90-degree angle simultaneously. To remove the needle from the skin, the skin is tapped three times quickly (again in a V shape) with the whole non-dominant hand, and the needle is withdrawn simultaneously with the final tap (tapping).

intervention group HSTT
PalmOTHER

The Palm Stimulator is 1.6 cm in diameter and 4 cm in length, and has a cylindrical, non-slip, and easy-to-grip structure designed to maximize palm contact. The Palm Stimulator is used by gripping it in the palm during injection. The device has blunt protrusions all around the palm to provide tactile stimulation. These blunt protrusions do not penetrate the skin but, according to gate control theory, create stimulation and close the pain gate in the spinal cord, reducing the pain perceived during injection. The researcher will show the Palm Stimulator, the device providing tactile stimulation, and allow examination. Twenty seconds before the injection, the Palm Stimulator will be placed in the palm of the child's dominant hand so that the child can grasp it. The child will be instructed to hold the device firmly in their palm throughout the procedure. After the injection is complete, the device will be removed from the child.

intervention group Palm

Eligibility Criteria

Age4 Years - 6 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Children aged between 4 and 6 years,
  • An intramuscular (IM) medication order was prescribed by a physician,
  • The IM injection was administered in the pediatric emergency department,
  • No history of chronic pain-causing illness,
  • No diagnosis of neurodevelopmental disorders,
  • Had not received any analgesic medications in the past 6 hours,
  • No history of syncope (fainting) during previous injections,
  • No diagnosis of mental retardation,
  • No scar tissue or muscle atrophy at the intended injection site,
  • Body mass index (BMI) percentile between the 10th and 90th percentiles for age and gender,
  • Both child and parent provided informed consent to participate in the study.

You may not qualify if:

  • Participants were excluded from the study if:
  • The child was younger than 4 or older than 6 years,
  • There was scar tissue or muscle atrophy at the injection site,
  • The child or parent had communication difficulties,
  • The child's BMI was below the 10th percentile (cachectic) or above the 90th percentile (obese),
  • Either the child or parent declined to participate in the research.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sakarya University

Sakarya, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Pain

Interventions

PALM protein, human

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Model Details: 32 intervention, 1 control
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

January 17, 2026

First Posted

January 26, 2026

Study Start

December 25, 2025

Primary Completion

January 15, 2026

Study Completion

January 17, 2026

Last Updated

January 26, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Ethically, patient information can be shared upon reasonable request without revealing their identities for security reasons

Locations